State Street Corp bought a new position in shares of Pulse Biosciences, Inc (NASDAQ:PLSE) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 131,437 shares of the company’s stock, valued at approximately $4,538,000. State Street Corp owned about 0.92% of Pulse Biosciences as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in PLSE. Vanguard Group Inc. raised its position in shares of Pulse Biosciences by 49.7% in the 2nd quarter. Vanguard Group Inc. now owns 267,810 shares of the company’s stock worth $9,247,000 after acquiring an additional 88,902 shares in the last quarter. Northern Trust Corp raised its position in shares of Pulse Biosciences by 859.3% in the 2nd quarter. Northern Trust Corp now owns 97,554 shares of the company’s stock worth $3,369,000 after acquiring an additional 87,385 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Pulse Biosciences by 21,473.2% in the 2nd quarter. Wells Fargo & Company MN now owns 53,933 shares of the company’s stock worth $1,862,000 after acquiring an additional 53,683 shares in the last quarter. TIAA FSB bought a new position in shares of Pulse Biosciences in the 2nd quarter worth about $943,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Pulse Biosciences in the 2nd quarter worth about $897,000. 9.35% of the stock is owned by institutional investors and hedge funds.
Pulse Biosciences, Inc (NASDAQ:PLSE) opened at $22.20 on Thursday. Pulse Biosciences, Inc has a 12-month low of $5.20 and a 12-month high of $39.50.
In other news, Director Mitchell E. Levinson bought 3,835 shares of Pulse Biosciences stock in a transaction dated Thursday, September 14th. The stock was bought at an average cost of $12.30 per share, for a total transaction of $47,170.50. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Maky Zanganeh bought 29,775 shares of Pulse Biosciences stock in a transaction dated Monday, September 18th. The stock was purchased at an average price of $13.36 per share, with a total value of $397,794.00. Following the completion of the purchase, the director now owns 315,725 shares in the company, valued at $4,218,086. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 2,466,429 shares of company stock valued at $36,893,301. 6.70% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “State Street Corp Takes Position in Pulse Biosciences, Inc (PLSE)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/07/state-street-corp-takes-position-in-pulse-biosciences-inc-plse.html.
Pulse Biosciences Profile
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences, Inc (NASDAQ:PLSE).
What are top analysts saying about Pulse Biosciences Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pulse Biosciences Inc and related companies.